ClearPoint Neuro, Inc. (CLPT): M&A transaction — ClearPoint Neuro completes acquisition of IRRAS for $5M cash + 1.325M shares

ClearPoint Neuro, Inc.

Acquisition closed Nov 20, 2025; IRRAS shareholders received $5M cash and 1.325M CLPT shares.
Earnout consideration: 25% of net sales of certain IRRAS products above thresholds over three one-year periods.
IRRAS brings IRRA flow fluid-exchange system for intracranial bleeding, 50+ active customers, and commercial team.
ClearPoint Neuro expects expanded presence in neurocritical care and enhanced commercial scale from the deal.

item 1.01 item 2.01 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ClearPoint Neuro, Inc. completed an acquisition involving IRRAS Holdings, Inc. for $5,000,000 in cash and 1,325,000 shares of Company common stock (closed 2025-11-20).

Action: acquisition
Counterparty: IRRAS Holdings, Inc.
Consideration: $5,000,000 in cash and 1,325,000 shares of Company common stock
Closing: 2025-11-20

Exact text from the filing

the “Merger”), with the Second Merger Sub surviving the Second Merger. Merger Consideration Pursuant to the Merger Agreement, the Company delivered closing consideration of $5,000,000 in cash and 1,325,000 shares of Company common stock to IRRAS shareholders (the “Closing Shares”). Earnout Consideration As additional consideration for IRRAS’ stockholders, the

View on SEC.gov

Browse all m&a transactions →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-290003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.